A Study of T-DXd in Participants with or without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer - DESTINY-B12

Study identifier:D9673C00007

ClinicalTrials.gov identifier:NCT04739761

EudraCT identifier:2020-005048-46

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis with Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Medical condition

Breast Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Trastuzumab Deruxtecan

Sex

All

Actual Enrollment

506

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 22 Jun 2021
Primary Completion Date: 08 Feb 2024
Study Completion Date: 08 Feb 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo

Inclusion and exclusion criteria